NADC30-Like Porcine Reproductive and Respiratory Syndrome in China



Kegong Tian1, 2, *
1 College of Animal Science and Veterinary Medicine, Henan Agricultural University, Zhengzhou, China
2 OIE Porcine Reproductive and Respiratory Syndrome Laboratory, Beijing, China


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 1125
Abstract HTML Views: 488
PDF Downloads: 527
ePub Downloads: 451
Total Views/Downloads: 2591
Unique Statistics:

Full-Text HTML Views: 542
Abstract HTML Views: 267
PDF Downloads: 177
ePub Downloads: 123
Total Views/Downloads: 1109



© 2017 Kegong Tian.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the College of Animal Science and Veterinary Medicine, Henan Agricultural University, Zhengzhou, China, 450002, Tel: + (86) 10-59198895, Fax: + (86) 10-59198899; E-mail: tiankg@263.net


Abstract

NADC30-like porcine reproductive and respiratory syndrome virus (PRRSV) has widely spread in China and become locally dominant virus strain in some provinces. Although they are not pathogenic as highly pathogenic PRRSV (HP-RRRSV) that outbreaks since 2006, NADC30-like PRRSVs distinguished themselves by high incidence of recombination with other virus strains which lead to change of virulence. The outbreaks of NADC30-like PRRSV in the vaccinated pig herds suggested that current commercial PRRSV vaccines cannot provide complete protection to the infection. In this review, we have described in detail the current situation of NADC30 PRRSV including epidemiology, genomic characterization, pathogenicity, and efficacy of current commercial vaccines in China.

Keywords: NADC30-like PRRSV, Recombination, Pathogenicity, Vaccine efficacy.